WorldWideScience

Sample records for cevre radyasyonu oelcuemleri

  1. Havaalan› Cevre Yonetim Sistemi

    OpenAIRE

    Vildan KORUL

    2003-01-01

    Today, as a connection point of air transportation the airports are playing an important role in development of the contemporary society. However, airports also causes both regional and global environmental pollution as a result of operations. Some measures to guarantee the international environmental standards that help the decreasing and controlling the noise, air and water pollution and ecological impacts of airports should be taken. In this study, the importance of environmental managemen...

  2. Erzurum Kenti Hava Kirliliği Sorununun Çözümünde Peyzaj Mimarlığı Açısından Alınması Gereken Önlemler / Precautions For Solving Air Pollution Problems In Erzurum

    OpenAIRE

    Öz Sezen, Işık; Yılmaz, Sevgi

    2011-01-01

    OZET: Bu ara.t.rma, Erzurum kentinin onemli bir cevre sorunu olan hava kirlili.ini olu.turan etmenleri belirlemek ve peyzaj mimarl... ac.s.ndan al.nmas. gereken onlemleri saptamak amac.yla yap.lm..t.r. Cevre Sorunlar. Ara.t.rma Merkezi Mudurlu.u�fne ba.l. 6 hava kirlili.i olcum istasyonundan al.nan son 10 y.ll.k verilerin ortalamalar.na gore, Erzurum kentinde en yuksek SO2 (kukurtdioksit) ortalamas. 314ƒÊg/m3, en yuksek partikul madde miktar. 226 ƒÊg/m3 ile kent merkezin...

  3. Arc saw development report

    International Nuclear Information System (INIS)

    The arc saw is one of the key components of the Contaminated Equipment Volume Reduction (CEVR) Program. This report describes the progress of the arc saw from its inception to its current developmental status. History of the arc saw and early contributors are discussed. Particular features of the arc saw and their advantages for CEVR are detailed. Development of the arc saw including theory of operation, pertinent experimental results, plans for the large arc saw and advanced control systems are covered. Associated topics such as potential applications for the arc saw and other arc saw installations in the world is also touched upon

  4. GÜNE? ENERJYLY SU ISITMA SYSTEMLERYNDE ISI BORUSU VE VAKUM TÜPÜ KULLANIMININ KARABÜK ?ARTLARINDA DENEYSEL OLARAK YNCELENMESY

    OpenAIRE

    GÜREL, Ali Etem; CAMUR, Dogu; Ergün, Alper

    2010-01-01

    Bu çaly?mada, güne? enerjili su ysytma sistemlerinde ysy borusu ve vakum tüpü uygulamalarynyn kar?yla?tyrylmasy amacyyla, toplam 0.7 m² yüzey alanyna sahip bir kollektör e?it iki bölüme ayrylarak bir kysmyna vakum tüpü, bir kysmyna ise tarafymyzdan imal edilen ysy borusu yerle?tirilmi? ve her iki uygulama 10 litre su hacmine sahip depolara monte edilmi?tir. Be? gün boyunca sistemlere ait güne? radyasyonu, depo suyu sycaklyklary ve dy? sycaklyk de?erleri kaydedilmi?tir. Bu veriler do?rultusun...

  5. The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C

    Directory of Open Access Journals (Sweden)

    Ioan Sporea

    2011-12-01

    Full Text Available Background: Multiple variables influencing the sustained virologic response (SVR in chronic hepatitis C have been evaluated. One of them is genetic polymorphism near the IL28B gene.Objectives: The aim of this study was to evaluate the influence of IL28B genotypes on SVR rates in a group of patients with chronic hepatitis C from the western part of Romania.Patients and Methods: A retrospective study was performed in 107 consecutive patients, previously treated with standard-of-care medication for chronic hepatitis C, identified from the databases of 2 centers. Patient demographics, viral load before treatment and at 12, 24, and 72 weeks from the treatment start, and IL28B genotype were evaluated.Results: Among the 107 patents in the study group, 54 patients had SVR (50.5%, and 62 (57.9% showed a complete early virologic response (cEVR. The SVR rates according to IL28B genotype were as follows: 73.1% in patients with genotype C/C, 40.9% in those with genotype C/T, and 57.1% in those with genotype T/T (i.e., 73.1% among patients with the C/C genotype vs. 43.7% among those with non-C/C genotypes; P = 0.0126. The cEVR rates were 80.8% in patients with the C/C genotype vs. 51.2% in those with non-C/C genotypes (P = 0.011.Conclusions: In our cohort of 107 Caucasian HCV patients, the SVR rate was 50.5% with standard-of-care treatment. The SVR rate was directly related to the IL28B genotype: 73.1% in the C/C genotype vs. 43.7% in non-C/C genotypes (P = 0.0126.

  6. Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.

    Science.gov (United States)

    Buti, M; Flisiak, R; Kao, J-H; Chuang, W-L; Streinu-Cercel, A; Tabak, F; Calistru, P; Goeser, T; Rasenack, J; Horban, A; Davis, G L; Alberti, A; Mazzella, G; Pol, S; Orsenigo, R; Brass, C

    2015-07-01

    Alisporivir (ALV) is an oral, investigational host-targeting agent, with pangenotypic activity against hepatitis C virus (HCV). This randomized, double-blind, placebo-controlled, Phase II study explored the efficacy and safety of ALV with peginterferon-α2a/ribavirin (PR) in patients with chronic HCV genotype 1 infection in whom prior PR had failed (43% relapsers, 34% null responders and 23% partial responders). Four-hundred-and-fifty-nine patients were randomized (1:1:1:1) to ALV 600 mg once daily (QD), ALV 800 mg QD, ALV 400 twice daily (BID) or placebo plus PR for 48 weeks. When the global ALV trial programme was put on clinical hold, all patients in this study had received ≥31 weeks of randomized treatment; patients completed 48 weeks on PR alone. All ALV groups demonstrated superior rates of complete early virologic response (cEVR; primary endpoint) vs PR alone (P ≤ 0.0131), with highest cEVR rate seen with ALV 400 mg BID (74% vs 36% with PR alone; P 40 weeks of randomized treatment, the SVR12 rate was 89% for ALV 400 mg BID vs 30% for PR alone (P = 0.0053). Rates of viral breakthrough and relapse were lowest with ALV 400 mg BID. One case of pancreatitis (fully recovered) occurred with ALV/PR. Common AEs were headache, fatigue, anaemia, neutropenia and nausea. Hypertension was infrequent, but more common with ALV. ALV merits further investigation in interferon-free regimens in combination with direct-acting antiviral agents. PMID:25412795

  7. Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China

    Directory of Open Access Journals (Sweden)

    Wangxia Tong

    2016-01-01

    Full Text Available Aim. Our aim is to survey the treatment effect of PEG-IFN plus ribavirin in patients infected with HCV genotype 6a in Guangdong and Guangxi province of China and investigate best course of antiviral treatment for patients with HCV-6a infection. Methods. 515 eligible patients received subcutaneous 180 μg PEG-IFNα-2a or 1.5 μg/kg PEG-IFNα-2b once weekly plus oral ribavirin. Primary outcome was SVR by intention-to-treat analysis. Secondary outcome was RVR, cEVR, ETR, and relapse rate. Results. SVR in patients with HCV-6a infection treated for 48 weeks was comparable to that in patients with HCV-2/3 infection (80.9% versus 82.5%, p=0.812 and higher than that in patients with HCV-1b infection (80.9% versus 67.2%, p=0.014. ETR (98.9% versus 90.6%, p=0.016, virological response at month 3 of end-of- treatment (88.8% versus 76.6%, p=0.044, SVR (80.9% versus 65.6%, p=0.032, and virological response at month 12 of end-of-treatment (76.4% versus 60.9%, p=0.04 in patients with HCV-6a infection treated for 48 weeks were higher than those in patients with HCV-6a infection treated for 24 weeks. Conclusion. SVR in patients with HCV-6a treated for 48 weeks was comparable to that in patients with HCV-2/3 infection and higher than that in patients with HCV-1b infection; patients with HCV-6a infection treated for 48 weeks had a superior treatment response than patients treated for 24 weeks.

  8. Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China

    Science.gov (United States)

    Tong, Wangxia; Zhu, Jianyun; Luo, Ning; Yang, Xiaohua; Lei, Zhiying; Huang, Xiaoliang; Zhao, Zhixin; Zhang, Xiaohong; Gao, Zhiliang; Jiang, Zhonghua

    2016-01-01

    Aim. Our aim is to survey the treatment effect of PEG-IFN plus ribavirin in patients infected with HCV genotype 6a in Guangdong and Guangxi province of China and investigate best course of antiviral treatment for patients with HCV-6a infection. Methods. 515 eligible patients received subcutaneous 180 μg PEG-IFNα-2a or 1.5 μg/kg PEG-IFNα-2b once weekly plus oral ribavirin. Primary outcome was SVR by intention-to-treat analysis. Secondary outcome was RVR, cEVR, ETR, and relapse rate. Results. SVR in patients with HCV-6a infection treated for 48 weeks was comparable to that in patients with HCV-2/3 infection (80.9% versus 82.5%, p = 0.812) and higher than that in patients with HCV-1b infection (80.9% versus 67.2%, p = 0.014). ETR (98.9% versus 90.6%, p = 0.016), virological response at month 3 of end-of- treatment (88.8% versus 76.6%, p = 0.044), SVR (80.9% versus 65.6%, p = 0.032), and virological response at month 12 of end-of-treatment (76.4% versus 60.9%, p = 0.04) in patients with HCV-6a infection treated for 48 weeks were higher than those in patients with HCV-6a infection treated for 24 weeks. Conclusion. SVR in patients with HCV-6a treated for 48 weeks was comparable to that in patients with HCV-2/3 infection and higher than that in patients with HCV-1b infection; patients with HCV-6a infection treated for 48 weeks had a superior treatment response than patients treated for 24 weeks. PMID:27034655

  9. 12例丙型肝炎肝硬化患者脾切除术后抗病毒治疗的临床分析%Clinical features of antiviral therapy in 12 patients with hepatitis C virus-related cirrhosis after splenectomy

    Institute of Scientific and Technical Information of China (English)

    马丽娜; 何智敏; 画伟; 陈新月

    2013-01-01

    Objective To evaluate the therapeutic effects and influencing factors of common antiviral therapy (low-dose interferon plus ribavirin,IFN+RBV) in patients with hepatitis C virus (HCV)-decompensated cirrhosis following splenectomy.Methods Twelve patients were treated postsurgery with low-dose IFN (300-500 MIU QOD) or pegylated (Peg)-IFN (50 μg/w) and RBV (0.6-0.9 g/d) for 72 weeks if carrying the 1b genotype or 48 weeks if carrying the 2a genotype.All patients were followed-up for 24 weeks after treatment completion to determine the virological response (VR)rates,measured as rapid (R)VR,complete early (cE)VR,24 hr (24)VR,and sustained (S)VR.Statistical comparisons were made using the t-test or rank sum test,and correlation analyses were made using the Chi-square test.Differences were considered significant at P < 0.05.Results All 12 patients completed the treatment course and follow-up.Three patients could not tolerate the Peg-IFN and were switched to IFN,and six patients developed hemolysis that required RBV dose adjustment.The VR rates were:25.0%,RVR; 50.0%,cEVR; 16.7%,24VR; 86.0%,SVR.Only one patient was a non-responder,and only one relapsed.Of the patients who achieved SVR,100% had shown RVR,83.3% showed cEVR,and 50.0% showed 24VR,suggesting that RVR and cEVR may effectively predict SVR.Conclusion Some HCV-decompensated cirrhosis patients may benefìt from antiviral therapy following surgical resolution of hypersplenism.The occurrence of RVR and cEVR in these patients is positively correlated with achieving SVR.Physician-patient communication during early antiviral treatment and close clinical monitoring accompanied by psychological counseling throughout promotes success of the treatment approach.%目的 对部分符合外科脾切除术指征且有治疗意愿的失代偿期丙型肝炎肝硬化患者行脾切除术后给予小剂量干扰素联合利巴韦林抗病毒治疗,观察其疗效,并分析与疗效相关的可能影响因素.